Astria Therapeutics Inc (ATXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,652 | -27,364 | -21,867 | -14,850 | -7,876 |
| Depreciation Amortization | 62 | 304 | 237 | 165 | 88 |
| Accounts payable and accrued liabilities | 342 | -632 | -203 | 650 | -468 |
| Other Working Capital | 272 | -1,934 | -1,194 | -175 | -897 |
| Other Operating Activity | 157 | 2,790 | 1,828 | 425 | 1,048 |
| Operating Cash Flow | $-6,819 | $-26,836 | $-21,199 | $-13,785 | $-8,105 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -27 | -27 | -9 | -9 |
| Sale Of Investment | N/A | 14,910 | 14,910 | 14,910 | 14,910 |
| Investing Cash Flow | $N/A | $14,883 | $14,883 | $14,901 | $14,901 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | -1,667 | N/A |
| Debt Repayment | -833 | -3,333 | -2,500 | N/A | -833 |
| Common Stock Issued | 8,313 | 8,059 | 6,933 | 6,324 | 2,236 |
| Financing Cash Flow | $7,480 | $4,726 | $4,433 | $4,657 | $1,403 |
| Beginning Cash Position | 16,482 | 23,709 | 23,709 | 23,709 | 23,709 |
| End Cash Position | 17,143 | 16,482 | 21,826 | 29,482 | 31,908 |
| Net Cash Flow | $661 | $-7,227 | $-1,883 | $5,773 | $8,199 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,819 | -26,836 | -21,199 | -13,785 | -8,105 |
| Capital Expenditure | N/A | -57 | -57 | -39 | -9 |
| Free Cash Flow | -6,819 | -26,893 | -21,256 | -13,824 | -8,114 |